Moderna/Merck Personalized mRNA Melanoma Cancer Shot Uses AI-Generated Design
A personalized mRNA melanoma cancer shot developed by Moderna and Merck using an AI generated design has met the primary endpoint in a late-stage phase 3 clinical trial.1 In August, the two pharmaceutical giants reported that, when combined with an existing treatment, the vaccine reduced the risk of melanoma returning or spreading. Cancer experts are enthusiastic […]